Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 27;12(12):1335.
doi: 10.3390/vaccines12121335.

Advancements in Nanoparticle-Based Adjuvants for Enhanced Tuberculosis Vaccination: A Review

Jiao Wang  1   2 , Zian Zhao  1 , Quan Wang  1 , Jingyu Shi  1 , Duo Wai-Chi Wong  1 , James Chung-Wai Cheung  1
Affiliations
Review

Advancements in Nanoparticle-Based Adjuvants for Enhanced Tuberculosis Vaccination: A Review

Jiao Wang et al. Vaccines (Basel). .

Abstract

Tuberculosis (TB) remains a leading cause of morbidity and mortality worldwide, necessitating the development of more effective vaccines. Nanoparticle-based adjuvants represent a promising approach to enhancing tuberculosis vaccine efficacy. This review focuses on the advantages of nanoparticulate-loaded vaccines, emphasizing their ability to improve antigen delivery, safety, and immunogenicity. We discuss the various types of nanoparticles and their unique physicochemical properties that contribute to improved antigen delivery and sustained immune activation. Additionally, we highlight the advantages of nanoparticle-based adjuvants in inducing strong cellular and humoral immunity, enhancing vaccine stability, and reducing adverse effects. Finally, we address current challenges and future perspectives in the application of these novel adjuvants, emphasizing their potential to transform TB vaccine strategies and ultimately contribute to better global health outcomes.

Keywords: adjuvants; nanoparticles; tuberculosis; vaccines.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Average size range of different nanoadjuvants: lipid-based nanoparticles (50–500 nm); polymer-based nanoparticles (50–500 nm); inorganic nanoparticles (<200 nm); hybrid nanoparticles (50–500 nm).
Figure 2
Figure 2
Schematic representation of nanocarriers. Different approaches can be utilized for the incorporation of targeting molecules (e.g., antigen, adjuvants, ligands, etc.) into/onto liposomes.
Figure 3
Figure 3
Characteristics of vaccine delivery systems with different nanocarriers in TB vaccines. A: target antigen to specific cells/organs. B: protect the antigen from degradation. C: slow release of antigen. D: enhance antigen uptake/presentation. E: dampen PAMP systemic toxicity. F: direct stimulatory effect of the APC or adjacent cells.
Figure 4
Figure 4
Different nanoparticle-based TB vaccine delivery systems function by activating cellular and humoral immunity to varying degrees.
See this image and copyright information in PMC

References

    1. Ghebreyesus T.A., Lima N.T. The TB Vaccine Accelerator Council: Harnessing the power of vaccines to end the tuberculosis epidemic. Lancet Infect. Dis. 2023;23:1222–1223. doi: 10.1016/S1473-3099(23)00589-3. - DOI - PubMed
    1. Zaman K. Tuberculosis: A global health problem. J. Health Popul. Nutr. 2010;28:111. doi: 10.3329/jhpn.v28i2.4879. - DOI - PMC - PubMed
    1. Reid M.J., Arinaminpathy N., Bloom A., Bloom B.R., Boehme C., Chaisson R., Chin D.P., Churchyard G., Cox H., Ditiu L. Building a tuberculosis-free world: The Lancet Commission on tuberculosis. Lancet. 2019;393:1331–1384. doi: 10.1016/S0140-6736(19)30024-8. - DOI - PubMed
    1. Bekale R.B., Du Plessis S.-M., Hsu N.-J., Sharma J.R., Sampson S.L., Jacobs M., Meyer M., Morse G.D., Dube A. Mycobacterium Tuberculosis and Interactions with the Host Immune System: Opportunities for Nanoparticle Based Immunotherapeutics and Vaccines. Pharm. Res. 2018;36:8. doi: 10.1007/s11095-018-2528-9. - DOI - PMC - PubMed
    1. Marks S.M., Flood J., Seaworth B., Hirsch-Moverman Y., Armstrong L., Mase S., Salcedo K., Oh P., Graviss E.A., Colson P.W. Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005–2007. Emerg. Infect. Dis. 2014;20:812. doi: 10.3201/eid2005.131037. - DOI - PMC - PubMed

LinkOut - more resources